Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 5/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 3/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21596337 | 0.97 | PIN1 (0.55) | PIN1TDP1RAB9AMEN1KMT2A | |
| SCHEMBL16597748 | 0.84 | SCN9A (0.54) | PIN1TDP1RAB9AMEN1KMT2A | |
| SCHEMBL26984449 | 0.81 | TDP1 (0.58) | PIN1TDP1RAB9AMEN1KMT2A | |
| SCHEMBL16670315 | 0.80 | KMT2A (0.50) | TDP1MEN1KMT2APARP10BTK | |
| SCHEMBL16670718 | 0.80 | BTK (0.53) | TDP1RAB9AMEN1KMT2APARP10 | |
| SCHEMBL16671203 | 0.79 | MEN1 (0.46) | TDP1RAB9AMEN1KMT2APARP10 | |
| SCHEMBL13919652 | 0.78 | XPO1 (0.60) | PIN1TDP1MEN1KMT2A | |
| SCHEMBL17673007 | 0.78 | PIN1 (0.56) | PIN1PARP10POLB | |
| SCHEMBL16669692 | 0.78 | RAB9A (0.57) | TDP1RAB9AMEN1KMT2APARP10 | |
| SCHEMBL26984232 | 0.77 | CYP1A2 (0.72) | PIN1TDP1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| EP-3060550-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-05-15 | — | — | EP | disclosed |
| EP-3060550-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-05-15 | — | — | EP | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-09-15 | — | — | US | disclosed |
| CN-105939998-A | Heteroaryl compounds as btk inhibitors and uses thereof | 默克专利有限公司 | 2016-09-14 | — | — | CN | disclosed |
| EP-3060550-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015061247-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-04-30 | — | — | WO | disclosed |
| WO-2015061247-A2 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264548-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | PIN1 1257/4885TDP1 1162/4885RAB9A 2628/4885 |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LCK | PIN1 1257/4885TDP1 1162/4885RAB9A 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.